Galactica Pharmaceuticals, Inc.
Developing a proprietary novel RAGE fusion protein, initially for the treatment of diabetes and diabetic complications.
Galactica's RAGE protein is the first molecule of any type to have demonstrated in vivo efficacy against at least two major diabetic complications - retinopathy and neuropathy. This is of enormous clinical significance, as many diabetics initially present with one major complication but subsequently develop multiple complications over time. In the U.S. alone, we spend over $200 billion per year taking care of diabetics.